Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Immunology›Heavy Chain Disease
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Heavy Chain Disease

Immunology · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A disorder of immunoglobulin synthesis in which large quantities of abnormal heavy chains are excreted in the urine.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (879 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A disorder of immunoglobulin synthesis in which large quantities of abnormal heavy chains are excreted in the urine. The amino acid sequences of the N-(amino-) terminal regions of these chains are normal, but they have a deletion extending from part of the variable domain through the first domain of the constant region, so that they cannot form cross-links to the light chains. The defect arises through faulty coupling of the variable (V) and constant (C) region genes.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Heavy Chain Diseases; gamma-Chain Disease; gamma Chain Disease; gamma-Chain Diseases; Franklin Disease; Franklin's Disease; Franklins Disease; mu-Chain Disease.

Where it fits in the MeSH classification

Broader topics
Paraproteinemias; Lymphoproliferative Disorders
Narrower topics
Immunoproliferative Small Intestinal Disease
See also
Immunoglobulin Heavy Chains

Research landscape

PubMed indexes 1,000 records tagged with the MeSH heading “Heavy Chain Disease” (counts retrieved 2026-10-29). 36 of them (3.6%) were published from 2020 onward, and the busiest period so far is through 1999 with 793 records.

Reviews account for 156 records (15.6%) and meta-analyses for 1. Randomized controlled trials number 0 (0.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 793 records; 2000-2009: 82 records; 2010-2019: 89 records; 2020 onward: 36 records793through 1999822000-2009892010-2019362020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 1999793
2000-200982
2010-201989
2020 onward36
Share of records by publication typeReviews: 15.6 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 0.0 percentReviews15.6% (156)Meta-analyses0.1% (1)Randomized controlled trials0.0% (0)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 1,000 PubMed records
TypeRecordsShare
Reviews15615.6%
Meta-analyses10.1%
Randomized controlled trials00.0%

Method: PubMed query "Heavy Chain Disease"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in immunology

Immune responses are studied in model organisms, in cells from donors and in patients, and the same pathway can behave differently across these settings. Mouse immune systems differ from human ones in important ways, and blood measurements may not reflect what happens in tissues. Clinical conclusions about immune-mediated disease or immunotherapy come mainly from controlled trials and long-term cohorts. Check the species and tissue studied, whether markers were linked to outcomes patients notice, and the follow-up time.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Widespread intronic polyadenylation diversifies immune cell transcriptomes
Singh I, Lee SH, Sperling AS, Samur MK, Tai YT, Fulciniti M, et al.
2018Research article
Design not recorded in structured metadata
146cc by
PMID 29712909 · DOI · PMC5928244
Screening differentially expressed genes between endometriosis and ovarian cancer to find new biomarkers for endometriosis
Lu Z, Gao Y
2021Research article
Design not recorded in structured metadata
32cc by
PMID 34409913 · DOI · PMC8381947
The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia
Chen D, Zheng J, Gerasimcik N, Lagerstedt K, Sjögren H, Abrahamsson J, et al.
2016Research article
Design not recorded in structured metadata
29cc by
PMID 27611867 · DOI · PMC5017602
Novel Laboratory Approaches in Heavy Chain Disease With Discordant Immunoglobulin Quantitation: A Case Report and Literature Review
Longhi E, Çeka A, Olivieri F, Moretti M, Sabbatinelli J
2026Review article
Design not recorded in structured metadata
0cc by
PMID 41856916 · DOI · PMC13163937

Widespread intronic polyadenylation diversifies immune cell transcriptomes [1]

Research article Singh I, Lee SH, Sperling AS, Samur MK, Tai YT, Fulciniti M, et al. · · 2018 · cited 146 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Alternative cleavage and polyadenylation (ApA) is known to alter untranslated region (3'UTR) length but can also recognize intronic polyadenylation (IpA) signals to generate transcripts that lose part or all of the coding region.
Closing excerpt
MM cells display a striking loss of IpA isoforms expressed in plasma cells, associated with shorter progression-free survival and impacting key genes in MM biology and response to lenalidomide.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (145 words)

Alternative cleavage and polyadenylation (ApA) is known to alter untranslated region (3'UTR) length but can also recognize intronic polyadenylation (IpA) signals to generate transcripts that lose part or all of the coding region. We analyzed 46 3'-seq and RNA-seq profiles from normal human tissues, primary immune cells, and multiple myeloma (MM) samples and created an atlas of 4927 high-confidence IpA events represented in these cell types. IpA isoforms are widely expressed in immune cells, differentially used during B-cell development or in different cellular environments, and can generate truncated proteins lacking C-terminal functional domains. This can mimic ectodomain shedding through loss of transmembrane domains or alter the binding specificity of proteins with DNA-binding or protein-protein interaction domains. MM cells display a striking loss of IpA isoforms expressed in plasma cells, associated with shorter progression-free survival and impacting key genes in MM biology and response to lenalidomide.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 29712909 · DOI · PMC5928244

Screening differentially expressed genes between endometriosis and ovarian cancer to find new biomarkers for endometriosis [2]

Research article Lu Z, Gao Y · · 2021 · cited 32 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
AimEndometriosis is one of the most common reproductive system diseases, but the mechanisms of disease progression are still unclear.
Closing excerpt
We screened relevant therapeutic agents for target genes in the drug database, and performed histological validation of target genes with both expression and survival analysis difference in cancer databases.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (296 words)

AimEndometriosis is one of the most common reproductive system diseases, but the mechanisms of disease progression are still unclear. Due to its high recurrence rate, searching for potential therapeutic biomarkers involved in the pathogenesis of endometriosis is an urgent issue.MethodsDue to the similarities between endometriosis and ovarian cancer, four endometriosis datasets and one ovarian cancer dataset were downloaded from Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified, followed by gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and protein-protein interaction (PPI) analyses. Then, we validated gene expression and performed survival analysis with ovarian serous cystadenocarcinoma (OV) datasets in TCGA/GTEx database, and searched for potential drugs in the Drug-Gene Interaction Database. Finally, we explored the miRNAs of key genes to find biomarkers associated with the recurrence of endometriosis.ResultsIn total, 104 DEGs were identified in the endometriosis datasets, and the main enriched GO functions included cell adhesion, extracellular exosome and actin binding. Fifty DEGs were identified between endometriosis and ovarian cancer datasets including 11 consistently regulated genes, and nine DEGs with significant expression in TCGA/GTEx. Only IGHM had both significant expression and an association with survival, three module DEGs and two significantly expressed DEGs had drug associations, and 10 DEGs had druggability.ConclusionsITGA7, ITGBL1 and SORBS1 may help us understand the invasive nature of endometriosis, and IGHM might be related to recurrence; moreover, these genes all may be potential therapeutic targets.KEY MESSAGEThis manuscript used a bioinformatics approach to find target genes for the treatment of endometriosis.This manuscript used a new approach to find target genes by drawing on common characteristics between ovarian cancer and endometriosis.We screened relevant therapeutic agents for target genes in the drug database, and performed histological validation of target genes with both expression and survival analysis difference in cancer databases.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34409913 · DOI · PMC8381947

The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia [3]

Research article Chen D, Zheng J, Gerasimcik N, Lagerstedt K, Sjögren H, Abrahamsson J, et al. · · 2016 · cited 29 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Precursor-B cell receptor (pre-BCR) signaling represents a crucial checkpoint at the pre-B cell stage.
Closing excerpt
Our findings suggest that BCP-ALL are arrested at different cellular stages, which relates to the expression pattern of the pre-BCR components that could serve as prognostic markers for high-risk pediatric BCP-ALL patients.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (199 words)

Precursor-B cell receptor (pre-BCR) signaling represents a crucial checkpoint at the pre-B cell stage. Aberrant pre-BCR signaling is considered as a key factor for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) development. BCP-ALL are believed to be arrested at the pre-BCR checkpoint independent of pre-BCR expression. However, the cellular stage at which BCP-ALL are arrested and whether this relates to expression of the pre-BCR components (IGHM, IGLL1 and VPREB1) is still unclear. Here, we show differential protein expression and copy number variation (CNV) patterns of the pre-BCR components in pediatric BCP-ALL. Moreover, analyzing six BCP-ALL data sets (n = 733), we demonstrate that TCF3-PBX1 ALL express high levels of IGHM, IGLL1 and VPREB1, and are arrested at the pre-B stage. By contrast, ETV6-RUNX1 ALL express low levels of IGHM or VPREB1, and are arrested at the pro-B stage. Irrespective of subtype, ALL with high levels of IGHM, IGLL1 and VPREB1 are arrested at the pre-B stage and correlate with good prognosis in high-risk pediatric BCP-ALL (n = 207). Our findings suggest that BCP-ALL are arrested at different cellular stages, which relates to the expression pattern of the pre-BCR components that could serve as prognostic markers for high-risk pediatric BCP-ALL patients.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 27611867 · DOI · PMC5017602

Novel Laboratory Approaches in Heavy Chain Disease With Discordant Immunoglobulin Quantitation: A Case Report and Literature Review [4]

Review article Longhi E, Çeka A, Olivieri F, Moretti M, Sabbatinelli J · · 2026

Abstract reading summary — source excerpts
Opening excerpt
BackgroundHeavy chain disease (HCD) is a rare plasma-cell neoplasm frequently linked to lymphoproliferative and autoimmune disorders.
Closing excerpt
This is necessary to ensure prompt and effective care for a rare condition, particularly with complex presentations like this case.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (239 words)

BackgroundHeavy chain disease (HCD) is a rare plasma-cell neoplasm frequently linked to lymphoproliferative and autoimmune disorders. Clinical presentation varies widely, with no conventional signs or symptoms. The prognosis is frequently uncertain, and there is currently no typical diagnosis or treatment. Truncated immunoglobulins' heavy chains (HCs) identification and bound light chains (LCs) exclusion are diagnostic requirements. The initial approach is laboratory-based, mostly from protein analysis, as serum protein electrophoresis (SPE), immunotyping (IT), and immunofixation (IFE) are usually the first diagnostic steps.MethodsA panel of tests resulted in low serum protein, so SPE, IT, and IFE were conducted. The findings established a spike's presence and γ-HC isotype, but differential diagnosis from gammopathies with LCs' low reactivity to reagents required further testing. Consequently, a molecular weight separation gel and immunoselection were executed.ResultsSPE showed a 29.4% (12.9 g/L) spike central to the γ-fraction, while IT resulted in a subtraction in the IgG window, later verified by serum IFE. Immunoselection showed no LC-HC link, excluding a gammopathy with difficult LC identification. The molecular weight gel revealed a 160 kDa band. This rare case of HCD presents unique complexity, also due to discordant IgG3-IgG quantitation, associated angioimmunoblastic lymphoma morphology, and EBV genome.ConclusionThe aim is to draw attention to the difficulties in diagnosing HCD and stress the importance of both advanced methods and a proper laboratory approach. This is necessary to ensure prompt and effective care for a rare condition, particularly with complex presentations like this case.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41856916 · DOI · PMC13163937

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease [5]
    Buxbaum J · Hematol Oncol Clin North Am · 1992 · cited 108 times (Europe PMC)
  • Research article Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases [6]
    Buxbaum J, Gallo G · Hematol Oncol Clin North Am · 1999 · cited 103 times (Europe PMC)
  • Research article Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms [7]
    Al-Saleem T, Al-Mondhiry H · Blood · 2005 · cited 101 times (Europe PMC)
  • Research article Heavy chain diseases: current findings and concepts [8]
    Seligmann M, Mihaesco E, Preud'homme JL, Danon F, Brouet JC · Immunol Rev · 1979 · cited 95 times (Europe PMC)
  • Research article Pathological study of alpha-chain disease, with special emphasis on evolution [9]
    Galian A, Lecestre MJ, Scotto J, Bognel C, Matuchansky C, Rambaud JC · Cancer · 1977 · cited 81 times (Europe PMC)
  • Research article Alpha-chain disease. Pathogenesis and relation to Mediterranean lymphoma [10]
    Rambaud JC, Matuchansky C · Lancet · 1973 · cited 49 times (Europe PMC)

References

  1. Singh I, Lee SH, Sperling AS, Samur MK, Tai YT, Fulciniti M, et al.. Widespread intronic polyadenylation diversifies immune cell transcriptomes. . 2018. PMID 29712909 · DOI · PMC5928244
  2. Lu Z, Gao Y. Screening differentially expressed genes between endometriosis and ovarian cancer to find new biomarkers for endometriosis. . 2021. PMID 34409913 · DOI · PMC8381947
  3. Chen D, Zheng J, Gerasimcik N, Lagerstedt K, Sjögren H, Abrahamsson J, et al.. The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia. . 2016. PMID 27611867 · DOI · PMC5017602
  4. Longhi E, Çeka A, Olivieri F, Moretti M, Sabbatinelli J. Novel Laboratory Approaches in Heavy Chain Disease With Discordant Immunoglobulin Quantitation: A Case Report and Literature Review. . 2026. PMID 41856916 · DOI · PMC13163937
  5. Buxbaum J. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am. 1992. PMID 1582976 · DOI
  6. Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am. 1999. PMID 10626147 · DOI
  7. Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood. 2005. PMID 15542584 · DOI
  8. Seligmann M, Mihaesco E, Preud'homme JL, Danon F, Brouet JC. Heavy chain diseases: current findings and concepts. Immunol Rev. 1979. PMID 121099 · DOI
  9. Galian A, Lecestre MJ, Scotto J, Bognel C, Matuchansky C, Rambaud JC. Pathological study of alpha-chain disease, with special emphasis on evolution. Cancer. 1977. PMID 404026 · DOI
  10. Rambaud JC, Matuchansky C. Alpha-chain disease. Pathogenesis and relation to Mediterranean lymphoma. Lancet. 1973. PMID 4122995 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Waldenstrom MacroglobulinemiaCancer and Oncology
  • AgammaglobulinemiaImmunology
  • Monoclonal Gammopathy of Undetermined SignificanceImmunology
  • CryoglobulinemiaCardiovascular Medicine
  • Multiple MyelomaCancer and Oncology
  • Castleman DiseaseImmunology

All 90 articles in Immunology →

At a glance

1,000
PubMed records on this heading
4%
published since 2020
156
review articles
0
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Waldenstrom MacroglobulinemiaCancer and Oncology
  • AgammaglobulinemiaImmunology
  • Monoclonal Gammopathy of Undetermined SignificanceImmunology
  • CryoglobulinemiaCardiovascular Medicine
  • Multiple MyelomaCancer and Oncology

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support